A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer

This study is ongoing, but not recruiting participants.

Sponsor:

Information provided by (Responsible Party):

Quest PharmaTech Inc.

ClinicalTrials.gov Identifier:

NCT01616303

First received: May 30, 2012

Last updated: March 29, 2016

Last verified: March 2016

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	June 2018
Primary Completion Date:	June 2014 (Final data collection date for primary outcome measure)